Hamstring Stretching Effective on Nonspecific Low Back Pain (Hams)

July 20, 2026 updated by: Eylül Pınar KISA, Biruni University

Does Hamstring Stretching Effective on Nonspecific Low Back Pain?"

Low back pain is one of the most common complaints in the world and can be considered a universal health problem for humanity. Low back pain is a multifactorial disease with multiple etiologies. Risk factors are difficult to identify. It is reported in the literature that 70-80% of the world's population has low back pain at some point in their lives, and 95% of this pain is mechanical. Mechanical low back pain (MBA) can be described as a clinical picture that develops as a result of overuse, strain, traumatization or deformation of the structures that make up the spine. In order to define low back pain mechanically, all organic causes such as inflammatory, infectious, tumoral, metabolic causes, fractures and pain reflected from internal organs must be excluded. The most common diseases that cause low back pain are; They are caused by mechanical factors and degenerative diseases. Mechanical and static stresses can lead to joint blockage, restricting the range of motion of the joint along with pain. Non-Specific many factors affect low back pain. Kim and Shin reported that asymmetry of hip extension range of motion of both hip joints was associated with nonspecific low back pain rather than simple hip extension range of motion, and they found that limiting hip extension was compensatory.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Istanbul
      • Istanbul, Istanbul, Turkey (Türkiye), 34720
        • Eylül Pınar Kısa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with complaints of low back pain,
  • NLBP for at least 12 weeks,
  • finger-to-ground distance greater than 0 cm; a passive straight-leg raising -(SLR) angle of less than 80°, measured with a hand-held goniometer;
  • normal mobility of the hip;
  • passive knee extension ≥25°,
  • VAS score between 3 and 7 will be included.

Exclusion Criteria:

  • People with a history of hamstring injury in the last two years,
  • fractures in the spine or lower extremities,
  • pregnancy,
  • leg length difference of more than 2 cm,
  • and obesity will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: exercise group
Exercise program and 3 way hamstring strech will be applied.
It consist of traditional exercises.
Other: control group
Just Exercise program will be applied.
It consist of traditional exercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Flexibility assessment
Time Frame: 0-4 week
During the Passive Knee Extension Test, participants will be positioned supine with the hip of the tested limb flexed to 90° while the contralateral limb will be stabilized. The examiner gradually extended the knee until resistance or discomfort will reported. The knee extension angle will be measured using a digital goniometer and recorded in degrees.
0-4 week
Flexibility assessment
Time Frame: 0-4 week
fingertip-to-floor (FTF) test, participants stood on a 20-cm step and will instructed to bend forward and reach toward the floor without flexing their knees. The distance between the third fingertip and the floor will measured using a tape measure and recorded in centimeters. The minimal detectable change (MDC) for the FTF test is reported as 4.5 cm
0-4 week
Flexibility assessment
Time Frame: 0-4 week
Sit- and-reach test (SRT) participants sİt with their knees fully extended and feet position against the testing box. They are instructed to reach forward as far as possible while keeping their knees extended. The furthest distance reached will recorded in centimeters
0-4 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functionality index
Time Frame: 0-4 week
Functional Rating Index (FDI) was obtained by combining similar structures of the neck disability index and the Osweestry low back pain disability index, and its validity and reliability have been proven. The validity and reliability of the Turkish version of this survey was conducted by Bayar et al. in 2004. FDI consists of 10 parts that measure the function of the spinal musculoskeletal (waist, neck pain) system and pain. Eight address activities of daily living that may be affected by the spinal condition. Two of them address 2 different characteristics of pain. Using a 5-choice scale for each item, the amount of current pain or perceived ability to function is ranked by selecting 5 response points. 0=no pain or full function, 1=mild pain or mild limitation, 2=moderate pain or moderate limitation, 3=severe pain or severe limitation, 4=worst pain or inability to function. Scoring varies between 0-40, and as the score increases, functional status worsens
0-4 week
Functional disability
Time Frame: 0-4 week
Functional disability will be assessed using the Oswestry Disability Index (ODI). The ODI consists of 10 items evaluating pain intensity and disability during daily activities. Each item will be scored from 0 to 5, with higher scores indicating greater disability. The Turkish version of the ODI has demonstrated acceptable validity and reliability (Yakut et al., 2004). ODI scores will be categorized as minimal (0-20), moderate (21-40), severe (41-60), crippled (61-80), and bed-bound (81-100) disability. A 30% improvement from baseline will be considered the threshold for clinically meaningful improvement in individuals with low back pain.
0-4 week
Pain status
Time Frame: 0-4 week
Pain status Patients pain status were evaluated with VAS between 0 and 10 for low back pain during movement. (No pain at 0 points, severe pain at 10 points)
0-4 week
Jump performance
Time Frame: 0-4 week
Vertical jump performance will be assessed using the squat jump (SJ) test. Participants will start from a semi-squat position without preparatory countermovement and will be instructed to jump as high as possible. Jump height will be measured using a Vertec system, which has demonstrated acceptable validity and reliability for vertical jump assessment. Three trials will be performed under standardized conditions, and the highest value will be recorded. Jump height will be calculated as the difference between standing reach height and maximal jump reach height and will be recorded in centimeters.
0-4 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 12, 2023

Primary Completion (Actual)

January 1, 2024

Study Completion (Actual)

August 10, 2024

Study Registration Dates

First Submitted

December 13, 2023

First Submitted That Met QC Criteria

February 19, 2025

First Posted (Actual)

February 20, 2025

Study Record Updates

Last Update Posted (Actual)

July 22, 2026

Last Update Submitted That Met QC Criteria

July 20, 2026

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe